Condition
Metastatic Anal Canal Carcinoma
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Recruiting1
Unknown1
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT02314169Phase 2Active Not Recruiting
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
NCT04221893Not ApplicableRecruiting
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
NCT02560298Phase 2Unknown
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
Showing all 3 trials